Synthesis and cytotoxic properties of 4,11-bis[(aminoethyl)amino]anthra[2,3-b]thiophene-5,10-diones, novel analogues of antitumor anthracene-9,10-diones

Bioorg Med Chem. 2009 Mar 1;17(5):1861-9. doi: 10.1016/j.bmc.2009.01.047. Epub 2009 Jan 27.

Abstract

We developed the synthesis of a series of thiophene-fused tetracyclic analogues of the antitumor drug ametantrone. The reactions included nucleophilic substitution of methoxy groups in 4,11-dimethoxyanthra[2,3-b]thiophene-5,10-diones with ethylenediamines, producing the derivatives of 4,11-diaminoanthra[2,3-b]thiophene-5,10-dione in good yields. Several compounds showed marked antiproliferative potency against doxorubicin-selected, P-glycoprotein-expressing tumor cells and p53(-/-) cells. The cytotoxicity of some novel compounds for P-glycoprotein-positive cells is highly dependent on N-substituent at the terminal amino group of ethylenediamine moiety. The cytotoxic potency of selected compounds correlated with their ability to attenuate the functions of topoisomerase I and telomerase, strongly suggesting that these enzymes are the major targets of antitumor activity of anthra[2,3-b]thiophene-5,10-dione derivatives.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / chemical synthesis*
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / toxicity*
  • Cell Line, Tumor
  • DNA Topoisomerases, Type I / metabolism
  • Drug Screening Assays, Antitumor
  • Humans
  • Inhibitory Concentration 50
  • Mitoxantrone / analogs & derivatives*
  • Mitoxantrone / chemical synthesis
  • Mitoxantrone / chemistry
  • Mitoxantrone / toxicity
  • Topoisomerase I Inhibitors

Substances

  • Antineoplastic Agents
  • Topoisomerase I Inhibitors
  • Mitoxantrone
  • DNA Topoisomerases, Type I
  • ametantrone